By Cecilia Butini 
 

Sanofi SA said Tuesday that it won't further advance the development of a messenger-RNA vaccine against Covid-19 and would instead focus on another type of shot, based on recombinant protein technology.

The French pharma major said it wouldn't make sense for it to advance its mRNA vaccine into a phase 3 trial, despite previously announcing positive results from a phase 1/2 trial.

"From a public-health perspective, mRNA Covid vaccines are widely available today and starting a placebo-controlled study in countries where vaccines are available would be extremely challenging," a company spokesman said.

 

Write to Cecilia Butini at cecilia.butini@wsj.com

 

(END) Dow Jones Newswires

September 28, 2021 04:13 ET (08:13 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Sep 2021 to Oct 2021 Click Here for more Sanofi Charts.
Sanofi (NASDAQ:SNY)
Historical Stock Chart
From Oct 2020 to Oct 2021 Click Here for more Sanofi Charts.